Who is sponsoring NCT00780039?

NCT00780039 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00780039?

Interventions in NCT00780039: Pegylated Liposomal Doxorubicin, Carboplatin.

What condition does NCT00780039 study?

NCT00780039 studies Ovarian Neoplasms.

Is NCT00780039 still recruiting?

NCT00780039 is currently completed. Last updated 15 May 2017.

Last reviewed 2017-05-15 · How we verify

NCT00780039

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Completed Phase 2 Last updated 15 May 2017

What this trial tests

Phase 2 trial testing Pegylated Liposomal Doxorubicin in Ovarian Neoplasms in 58 participants. Completed in 6 September 2007.

Timeline

1 October 2003

Primary endpoint
6 September 2007

6 September 2007

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	1 October 2003
Primary completion	6 September 2007
Estimated completion	6 September 2007

Drugs / interventions tested

Pegylated Liposomal Doxorubicin
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Ovarian Neoplasms — all drugs for Ovarian Neoplasms →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, female only, with Ovarian Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Doxorubicin has been used to treat ovarian cancer as part of different combination therapies, but high cumulative doses should be avoided because of the risk of cardiotoxicity. Pegylated Liposomal Doxorubicin (Caelyx) has been developed to reduce the risk of cardiotoxicity. The purpose of this study is to evaluate the safety and efficacy of Caelyx in combination with carboplatin in women with recurrent ovarian cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.
Gralewska P, Gajek A, Marczak A, Rogalska A. · · 2024 · cited 21× · PMID 39125873 · DOI 10.3390/ijms25158304

Verify or expand the search:

Other trials of Pegylated Liposomal Doxorubicin

Trials testing the same drug.

NCT06014528 — IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment · Phase 2 · recruiting
NCT05774275 — The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma · Phase 1, PHASE2 · recruiting
NCT03994107 — Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer · Phase 1, PHASE2 · unknown
NCT03161132 — Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin · Phase 2 · completed
NCT03071926 — Metronomic PLD in Patients With Primary Endocrine Resistant ABC · Phase 2 · unknown

Other recruiting trials for Ovarian Neoplasms

Currently open trials in the same condition.

NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00780039 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 15 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00780039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing